The telomere hypothesis for progressive liver cirrhosis

Journal of Hepatology

Volumn 38, Issue 3, 2003, Pages 378-379

  Murphy, Frank ^a   Iredale, John ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

APOPTOSIS; CELL AGING; CELL DESTRUCTION; DISEASE COURSE; ENZYME ACTIVITY; GENE DELETION; GENE THERAPY; HYPOTHESIS; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER REGENERATION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SHORT SURVEY; STELLATE CELL; TELOMERE; TRANSGENIC MOUSE;

EID: 0037337546     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00405-1     Document Type: Short Survey

References (13)

1. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
2. Wanless I, Nakashima E, Sherman M. Regression of human cirrhosis. morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124(11):1599-1607.
3. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-423.
4. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-985.
5. Schiff ER, Heathcote J, Dienstag JL, Hann L, Woessner M, Brown N, et al. Improvements in liver histology and cirrhosis with extended lamivudine therapy. Hepatology 2000;32(4):296A.
6. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
7. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-1137.
8. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-942.
9. Milani S, Schuppan D, Herbst H, Surrenti C. Expression of transforming growth factor beta, in normal and fibrotic human liver. In: Gressner A, Ramadori G, editors. Molecular and cell biology of liver fibrogenesis, Dordrecht: Kluwer Academic Publishers, 1992. pp. 254-262.
10. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000;287:1185-1187.
11. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999;180:10-18.
12. Greenberg RA, Chin L, Femino A, Xiao Q, Hann SR, Adams RR, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(-delta2/3) cancer-prone mouse. Cell 1999;97:515-525.
13. Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T, et al. Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology 1998;27:402-406.